Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations (PROSPERO). - PROSPERO

Study identifier:D9180C00008

ClinicalTrials.gov identifier:NCT05742802

EudraCT identifier:N/A

CTIS identifier:2022-501063-41-00

Recruiting

Official Title

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO).

Medical condition

Chronic obstructive pulmonary disease (COPD)

Phase

Phase 3

Healthy volunteers

No

Study drug

Tozorakimab 1, Tozorakimab 2, Placebo

Sex

All

Estimated Enrollment

1596

Study type

Interventional

Age

40 Years - 130 Years

Date

Study Start Date: 06 Mar 2023
Estimated Primary Completion Date: 16 Jun 2026
Estimated Study Completion Date: 17 Aug 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria